SHR7390

DRUG4 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Fudan University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Conditions

Breast CancerMetastatic CancerMetastatic Castration-resistant Prostate CancerSolid Tumor

Phase 1

Phase I Study of SHR7390 in Patients With Advanced Solid Tumors

Jiangsu HengRui Medicine Co., Ltd.Solid Tumor

Start: 2016-11-30End: 2019-07-31Target: 60Updated: 2019-01-15

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

TerminatedNCT03182673

Jiangsu HengRui Medicine Co., Ltd.Solid Tumor

Start: 2017-07-24End: 2019-06-12Updated: 2022-09-01

Phase 2

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

Fudan UniversityBreast Cancer, Metastatic Cancer

Start: 2020-05-01End: 2025-04-01Target: 319Updated: 2022-07-26

SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

CompletedNCT04676607

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolMetastatic Castration-resistant Prostate Cancer

Start: 2020-12-17End: 2023-06-12Updated: 2023-06-13

Related Papers

Abstract PO1-15-07: Subtyping-directed precision treatment refines traditional one-size-fits-all therapy in HR+/HER2- breast cancer: a sub-study of the MULAN umbrella trial

Cancer Research2024-05-02

A phase I study of SHR7390 plus camrelizumab in advanced/metastatic colorectal cancer.

Journal of Clinical Oncology2021-05-201 citations